Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a randomized double-blind placebo-controlled study of CKD-506 in adults with moderate-to-severe rheumatoid arthritis and inadequate response to methotrexate
2018-001377-24Phase 2Completed
- Sponsor
- Chong Kun Dang
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing CKD-506 with Placebo (2 arms). Primary endpoint: Change from baseline in DAS28(CRP). Started Oct 2019; status: completed.
02
Drugs
CKD-506
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2018-001377-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001377-24.